Figure 2: Schematic illustration of the high-throughput screening method for identifying effective Aβ-aggregation inhibitors. | Nature Communications

Figure 2: Schematic illustration of the high-throughput screening method for identifying effective Aβ-aggregation inhibitors.

From: Transition-metal-substituted polyoxometalate derivatives as functional anti-amyloid agents for Alzheimer’s disease

Figure 2

In the absence of inhibitors, the Aβ42 portion of the fusion aggregates rapidly and causes the entire Aβ42–ECFP fusion to misfold and aggregate (left). Therefore, no fluorescence is observed. However, inhibition of Aβ42 aggregation enables CFP to form its native fluorescent structure (middle, right).

Back to article page